The FCR-1: Initial validation of a single-item measure of fear of cancer recurrence

Menée au Canada, cette étude analyse l'intérêt d'un outil permettant de détecter la peur de la récidive chez des patients ayant survécu à un cancer

Résumé en anglais

Objective : Fear of cancer recurrence (FCR) is characterized by the fear, worry, or concern that cancer will come back or progress. The negative effects associated with FCR are consistently identified by cancer survivors as one of their most prominent unmet needs. Current measures of FCR can be long, complex, and burdensome for survivors to complete. The objective of the present study is to develop and validate a one‐item measure of FCR.

Methods : The ability of the FCR‐1 to detect change in FCR over time was analyzed using a repeated‐measures ANOVA and paired‐samples t‐tests. Pearson correlations were used to measure the concurrent, convergent and discriminant validity of the FCR‐1, and a ROC analysis was conducted to determine an optimal clinical cut‐off score.

Results : The FCR‐1 was found to be responsive to change in FCR over time. It demonstrated concurrent validity with the FCRI (r = 0.395, P = 0.010), and convergent validity with the Mishel Uncertainty in Illness Scale (r = .493, P = .001) and the Reassurance Questionnaire (r = .325, P = .044). Discriminant validity was confirmed when the FCR‐1 did not significantly correlate with unrelated measures. A ROC analysis pinpointed an optimal clinical cut‐off score of 45.0.

Conclusions : The FCR‐1 is a promising tool that can be incorporated in clinical and research settings. Due to its brevity, the care needs of highly distressed patients can be met quickly and efficiently. In research setting, the FCR‐1 can reduce the cognitive burden experienced by survivors.